Multicenter prospective cohort study on the development of benign gallbladder disease and molecular analysis of bile composition in non-alcoholic fatty liver disease

Hanyang University Seoul Hospital0 个研究点目标入组 780 人开始时间: 待定最近更新: 2020年8月18日

试验速览

暂无简介。

•1. Patients hospitalized for cholecystectomy due to a benign disease of the gallbladder (gallstone or gallbladder polyp)
•2. 19 to 80

•1. For acute cholecystitis, grade II & III of Tokyo guideline 2018
•2. In case of acute cholecystitis, hepatitis level is more than 5 times the upper limit of normal.
•3. When jaundice level is more than 3 times the normal upper limit due to acute inflammation
•4. If there is a tendency to hemorrhage due to prothrombin time less than 50,000 prolonged 1.5 times or more
•5. In the past 2 years, alcoholic liver disease is suspected with a weekly alcohol consumption of 210g or more in men and 140g or more in women.
•6. A case of liver disease caused by chronic hepatitis B or C
•7. If you have a history of taking medications that can cause fatty liver
•A. Glucocorticoid
•B. Tamoxifen
•C. Methotrexate
•D. Valproate
•E. Amiodarone
•F. 5-fluorouracil
•G. Irinotecan
•H. Highly active antiretroviral therapy (HARRT)
•8. If you have a genetic disease that causes fatty liver
•A. Abetalipoproteinemia
•B. Familial hypobetalipoproteinemia
•C. Familial combined hyperlipidemia
•D. Glycogen storage disease
•E. Lipodystrophy
•F. Weber-Christian disease

发起方

Hanyang University Seoul Hospital